Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 2 of 2 entries
Sorted by: Best Match Show Resources per page
Synergistic inhibitory effects of low-dose decitabine in combination with bortezomib in the AML cell line Kasumi-1.

Experimental and therapeutic medicine

Mpakou V, Spathis A, Bouhla A, Mpazani E, Papageorgiou S, Gkontopoulos K, Glezou E, Thomopoulos T, Foukas P, Pappa V.
PMID: 33488804
Exp Ther Med. 2021 Mar;21(3):195. doi: 10.3892/etm.2021.9628. Epub 2021 Jan 08.

In the present study, the ability of the proteasome inhibitor bortezomib (BZ), an oxidative stress-inducing agent, to sensitize acute myeloid leukemia (AML) cells to decitabine (Dacogen

Data of sperm-entry inability in .

Data in brief

Velentzas AD, Velentzas PD, Katarachia S, Mpakou VE, Papassideri IS, Stravopodis DJ.
PMID: 28443296
Data Brief. 2017 Apr 08;12:180-183. doi: 10.1016/j.dib.2017.03.052. eCollection 2017 Jun.

This paper presents data associated with the research article entitled "Targeted downregulation of s36 protein unearths its cardinal role in chorion biogenesis and architecture during

Showing 1 to 2 of 2 entries